soleno therapeutics, inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. the company is currently advancing its lead candidate, dccr, a once-daily oral tablet for the treatment of pws, into a phase iii clinical development program in early 2018.
Company profile
Ticker
SLNO
Exchange
Website
CEO
Anish Bhatnagar
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Integer • Masimo • Natus Medical • LivaNova • BioPlus Acquisition • QT Imaging • Outset Medical ...
Former names
Capnia, Inc.
SEC CIK
Corporate docs
Subsidiaries
Soleno Therapeutics U.K. Ltd. • Soleno Therapeutics Europe Ltd. • Essentialis, Inc. ...
SLNO stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
22 Apr 24
DEF 14A
Definitive proxy
22 Apr 24
8-K
Departure of Directors or Certain Officers
22 Apr 24
8-K
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
7 Mar 24
10-K
2023 FY
Annual report
6 Mar 24
S-8
Registration of securities for employees
31 Jan 24
8-K
Departure of Directors or Certain Officers
30 Jan 24
S-8
Registration of securities for employees
17 Jan 24
8-K
Departure of Directors or Certain Officers
5 Jan 24
S-3ASR
Automatic shelf registration
2 Jan 24
Latest ownership filings
4
Kristen Yen
3 Apr 24
4
James H Mackaness
3 Apr 24
4
Patricia C Hirano
3 Apr 24
4
Bhatnagar Anish
3 Apr 24
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 24
SC 13G/A
COMMODORE CAPITAL LP
14 Feb 24
SC 13G/A
JANUS HENDERSON GROUP PLC
13 Feb 24
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
7 Feb 24
4
Kristen Yen
29 Jan 24
4
Patricia C Hirano
29 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 52.44 mm | 52.44 mm | 52.44 mm | 52.44 mm | 52.44 mm | 52.44 mm |
Cash burn (monthly) | (no burn) | (no burn) | 3.46 mm | 2.76 mm | 2.11 mm | 1.98 mm |
Cash used (since last report) | n/a | n/a | 23.51 mm | 18.73 mm | 14.34 mm | 13.46 mm |
Cash remaining | n/a | n/a | 28.93 mm | 33.71 mm | 38.10 mm | 38.98 mm |
Runway (months of cash) | n/a | n/a | 8.4 | 12.2 | 18.1 | 19.7 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 58 |
Opened positions | 53 |
Closed positions | 0 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 596.99 bn |
Total shares | 44.86 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Jack W. Schuler Living Trust | 11.91 mm | $35.02 mm |
Vivo Opportunity Fund | 8.42 mm | $35.36 mm |
Larry N Feinberg | 3.73 mm | $7.20 mm |
Vivo Capital | 3.20 mm | $94.52 bn |
Perceptive Advisors | 3.07 mm | $90.73 bn |
CG Carlyle Group Inc | 2.29 mm | $67.43 bn |
JHG Janus Henderson | 2.20 mm | $65.00 bn |
Adage Capital Partners GP, L.L.C. | 1.33 mm | $39.16 bn |
Ra Capital Management | 1.24 mm | $36.56 bn |
Fairmount Funds Management | 1.14 mm | $33.71 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | Anish Bhatnagar | Common Stock | Sell | Dispose S | No | No | 41.6671 | 7,597 | 316.54 k | 152,790 |
1 Apr 24 | Anish Bhatnagar | Common Stock | Sell | Dispose S | No | No | 41.1227 | 11,383 | 468.10 k | 160,387 |
1 Apr 24 | Hirano Patricia C | Common Stock | Sell | Dispose S | No | No | 41.6671 | 888 | 37.00 k | 50,924 |
1 Apr 24 | Hirano Patricia C | Common Stock | Sell | Dispose S | No | No | 41.1227 | 1,330 | 54.69 k | 41,812 |
1 Apr 24 | James H Mackaness | Common Stock | Sell | Dispose S | No | No | 41.6671 | 2,071 | 86.29 k | 62,953 |
1 Apr 24 | James H Mackaness | Common Stock | Sell | Dispose S | No | No | 41.1227 | 3,104 | 127.64 k | 65,024 |
1 Apr 24 | Yen Kristen | Common Stock | Sell | Dispose S | No | No | 41.6671 | 888 | 37.00 k | 23,422 |
1 Apr 24 | Yen Kristen | Common Stock | Sell | Dispose S | No | No | 41.1227 | 1,330 | 54.69 k | 24,310 |
25 Jan 24 | Anish Bhatnagar | Common Stock | Sell | Dispose S | No | No | 48.3 | 2,527 | 122.05 k | 171,770 |